In article Matveeva et al.,1 published online on 13 November 2018 in Wiley Online Library (wileyonlinelibrary.com), SATOR Therapeutics BioEnterprise was added in the Funding Information. Acknowledgment section was also changed to “The study was supported by the grant from the Center of Strategic Planning, The Ministry of Healthcare of the Russian Federation (project code 1.1096) and by SATOR Therapeutics BioEnterprise.”.
. CORRIGENDUM. Rev Med Virol. 2019;29:e2035. 10.1002/rmv.2035
REFERENCE
- 1. Matveeva OV, Chumakov PM. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev Med Virol. 2018;28(6):e2008. 10.1002/rmv.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]